<DOC>
	<DOCNO>NCT00841373</DOCNO>
	<brief_summary>The object study compare treatment iris/angle neovascularization panretinal photocoagulation ( laser ) treatment panretinal photocoagulation anti-angiogenic drug : ranibizumab .</brief_summary>
	<brief_title>Ranibizumab Supplementing Panretinal Photocoagulation Treatment Iris/Angle Neovascularization Retinal Ischemic Disease</brief_title>
	<detailed_description>A.To obtain preliminary data safety tolerability ranibizumab ( 0.5 mg ) patient new progressive neovascularization iris angle due retinal ischemic disease addition treatment PRP use incidence severity adverse event identify subjenc reporting vital sign , ocular examition . B.To assess proportion patient fail experience regression iris angle neovascularization document clinical examination , iris florescein angiography gonioscopic evaluation .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>All subject must meet follow criterion eligible study entry : 1 . Signed informed consent authorization use disclosure protect health information 2 . Age = 18 year 3 . Presence iris neovascularization angle neovascularization due retinal ischemic disease new onset note progress recently slit lamp examination gonioscopy 4 . Best correct visual acuity study eye 20/20 ( Snellen equivalent use EDTRS protocol 4 meter ) light perception . Only one eye enrol study . If eye eligible , investigator select eye enrol . Visual acuity nonstudy eye must better light perception 5 . Patient able willing return schedule visit 1 . Use intraocular periocular injection steroid ( , example triamcinolone ) study eye within 3 month study 2 . Use intraocular injection antiangiogenic drug study eye participation clinical trial use antiangiogenic treatment within 45 day enrollment study . 3 . Acute endophthalmitis within 1 month . 4 . Recent rhegmatogenous retinal detachment macular hole surgery within last 2 month 5 . Uncontrolled uveitis last month . 6 . Treatment PRP within 2 week study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Retinal ischemia : Iris/Angle Neovascularization</keyword>
</DOC>